GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Akorn and Azad Ink Glaucoma Deal

  • Akorn signed a definitive agreement with Azad Pharma related to the development and supply of three candidates for the treatment of glaucoma. The companies report that the products, Latanoprost, Bimatoprost, and Travoprost, have a total U.S. market-size of $870 million, according to 2006 IMS data. 

    The drug products are expected to be manufactured by Taejoon Pharmaceutical.  Taejoon and Azad will complete the regulatory dossiers and upon ANDA approval, will manufacture and supply the products to Akorn in a blow-fill seal container closure system. 

    Akorn will be responsible for the regulatory filings of the ANDA's and will own  them. As part of this Agreement, Akorn will have exclusive marketing and distribution rights for the three drug products in the U.S. and Canada.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?